Literature DB >> 3028665

Peripheral DTIC neurotoxicity: a case report.

M Amichetti, S Piffer, R Valdagni, G Ambrosini, M Piazza.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3028665     DOI： 10.1007/BF00296264

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


× No keyword cloud information.
  9 in total

1.  A possible neurologic complication of DTIC.

Authors:  A H Paterson; T A McPherson
Journal:  Cancer Treat Rep       Date:  1977 Jan-Feb

Review 2.  Neurotoxicity of commonly used antineoplastic agents (first of two parts).

Authors:  H D Weiss; M D Walker; P H Wiernik
Journal:  N Engl J Med       Date:  1974-07-11       Impact factor: 91.245

3.  Chemotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and dactinomycin.

Authors:  R E Gerner; G E Moore; M S Didolkar
Journal:  Cancer       Date:  1973-10       Impact factor: 6.860

4.  History and development of DTIC (NSC-45388).

Authors:  S A Schepartz
Journal:  Cancer Treat Rep       Date:  1976-02

5.  Role of DTIC (NSC-45388) in the chemotherapy of sarcomas.

Authors:  J A Gottlieb; R S Benjamin; L H Baker; R M O'Bryan; J G Sinkovics; B Hoogstraten; J M Quagliana; S E Rivkin; G P Bodey; V Rodriguez; G R Blumenschein; J H Saiki; C Coltman; M A Burgess; P Sullivan; T Thigpen; R Bottomley; S Balcerzak; T E Moon
Journal:  Cancer Treat Rep       Date:  1976-02

Review 6.  DTIC (NSC-45388) in malignant melanoma: a perspective.

Authors:  R L Comis
Journal:  Cancer Treat Rep       Date:  1976-02

7.  Neurotoxicity of antineoplastic drugs.

Authors:  R S Kaplan; P H Wiernik
Journal:  Semin Oncol       Date:  1982-03       Impact factor: 4.929

8.  Central nervous system complications after combination treatment with adriamycin (NSC-123127) and 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388).

Authors:  R A Gams; J T Carpenter
Journal:  Cancer Chemother Rep       Date:  1974 Sep-Oct

9.  Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP.

Authors:  G Bonadonna; R Zucali; S Monfardini; M De Lena; C Uslenghi
Journal:  Cancer       Date:  1975-07       Impact factor: 6.860
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.